Abstract:
:Cancer-associated fibroblasts have been shown to inhibit or stimulate tumor growth depending on stage, grade, and tumor type. It remains unclear, however, the effect of endometrial-cancer-associated fibroblasts on hormone-driven responses in endometrial cancer. In this study, we investigated the effect of normal and cancer-associated stromal cells from patients with and without endometrial cancer on endometrial tumor growth in response to estradiol (E2) and progesterone (P4). Compared to benign endometrial stromal cells, the low-grade and high-grade cancer-associated stromal cells exhibited a blunted hormone response for proliferation as well as IGFBP1 secretion. Additional analysis of the influence of stromal cells on hormone-driven tumor growth was done by mixing stromal cells from benign, low-grade, or high-grade tumors, with Ishikawa cells for subcutaneous tumor formation. The presence of both benign and high-grade cancer-associated stromal cells increased estradiol-driven xenografted tumor growth compared to Ishikawa cells alone. Low-grade cancer-associated stromal cells did not significantly influence hormone-regulated tumor growth. Addition of P4 attenuated tumor growth in Ishikawa + benign or high-grade stromal cells, but not in Ishikawa cells alone or with low-grade stromal cells. Using an angiogenesis focused real-time array TGFA, TGFB2 and TGFBR1 and VEGFC were identified as potential candidates for hormone-influenced growth regulation of tumors in the presence of benign and high-grade stromal cells. In summary, endometrial-cancer-associated cells responded differently to in vitro hormone treatment compared to benign endometrial stromal cells. Additionally, presence of stromal cells differentially influenced hormone-driven xenograft growth in vivo depending on the disease status of the stromal cells.
journal_name
Horm Cancerjournal_title
Hormones & cancerauthors
Pineda MJ,Lu Z,Cao D,Kim JJdoi
10.1007/s12672-015-0223-4subject
Has Abstractpub_date
2015-08-01 00:00:00pages
131-41issue
4eissn
1868-8497issn
1868-8500journal_volume
6pub_type
杂志文章abstract::Adjuvant glucocorticoid treatment is routinely used in the treatment of ovarian cancer to mitigate the undesirable side effects of chemotherapy, thereby enhancing tolerability to higher cytotoxic drug doses and frequency of treatment cycles. However, in vitro and preclinical in vivo and ex vivo studies indicate that g...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-017-0319-0
更新日期:2018-04-01 00:00:00
abstract::Endometrial cancer is the fourth most common malignancy among women and is a major cause of morbidity contributing to approximately 8,200 annual deaths in the USA. Despite advances to the understanding of endometrial cancer, novel interventions for the disease are necessary given that many tumors become refractory to ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-013-0157-7
更新日期:2013-12-01 00:00:00
abstract::Tetraiodothyroacetic acid (tetrac) and its nanoparticle formulation (Tetrac NP) act at an integrin cell surface receptor to inhibit tumor cell proliferation and tumor-related angiogenesis. Human pancreatic cancer cell (PANC-1 and MPanc96) xenografts were established in nude mice, and the effects of tetrac versus Tetra...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-013-0137-y
更新日期:2013-06-01 00:00:00
abstract::The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor best known for its ability to mediate the effects of environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin), polycyclic aromatic hydrocarbons (PAHs), benzene, and polychlorinated biphenyls (PCBs) through the initi...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-017-0300-y
更新日期:2017-08-01 00:00:00
abstract::Differential utilization of cancer screening between populations could lead to changes in cancer disparities. Evaluating incidence rates trends is one means of monitoring these disparities. Using Surveillance, Epidemiology, and End Results data, we compared annual percent changes (APC) in age-adjusted incidence rates ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-009-0002-1
更新日期:2010-02-01 00:00:00
abstract::Genetic variants in CYP19A1, the gene encoding aromatase, have been reported to be associated with circulating estrogen concentrations, a key risk factor for breast cancer. The mechanism underlying this association is still unclear; it has been suggested that some of these variants may alter the expression and/or acti...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-017-0317-2
更新日期:2018-04-01 00:00:00
abstract::The pathological diagnosis of adrenocortical carcinoma (ACC) is still challenging for its rarity and the presence of special variants (pediatric, oncocytic, myxoid, and sarcomatoid). It is based on the recognition at light microscopy of at least three among nine morphological parameters, according to the Weiss scoring...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-011-0088-0
更新日期:2011-12-01 00:00:00
abstract::Mitotic checkpoint is a fundamental mechanism involved in fidelity mitotic chromosome segregation, and its alteration results in progression of human malignancies. In this study, we examined expression profiles of seven mitotic checkpoint genes in 20 breast carcinomas using microarray analysis. Results demonstrated th...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-012-0130-x
更新日期:2013-04-01 00:00:00
abstract::In hepatocellular carcinoma (HCC), the hypoxic tumor microenvironment can drive enhance tumor malignancy and recurrence. The microRNA (miRNA) miR-196-5p has been shown to modulate the progression of several cancer types, but its roles in HCC remain uncertain. In the present report we observed significant miR-196-5p do...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-019-00370-5
更新日期:2019-12-01 00:00:00
abstract::The androgen receptor (AR) has context-dependent roles in breast cancer growth and progression. Overall, high tumor AR levels predict a favorable patient outcome, but several studies have established a tumor promotional role for AR, particularly in supporting the growth of estrogen receptor positive (ER-positive) brea...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-017-0302-9
更新日期:2017-12-01 00:00:00
abstract::Recent observations connected DNA cytosine deaminase APOBEC3B to the genetic evolution of breast cancer. We addressed whether APOBEC3B is associated with breast cancer clinical outcomes. APOBEC3B messenger RNA (mRNA) levels were related in 1,491 primary breast cancers to disease-free (DFS), metastasis-free (MFS), and ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-014-0196-8
更新日期:2014-12-01 00:00:00
abstract::Silent corticotrophins adenomas (SCAs) are clinically silent and non-secreting but immunostain positively for ACTH. We hypothesize that SCAs comprise both corticotroph and gonadotroph characteristics. Cohort analysis from 1994-2008 with follow-up time ranging from 1-15 years in a tertiary referral center. We compared ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0014-x
更新日期:2010-04-01 00:00:00
abstract::The prostate is a luminal secretory tissue whose function is regulated by male sex hormones. Castration produces involution of the prostate to a reversible basal state, and as the majority of prostate cancers also have a luminal phenotype, drug-induced castration is a front line therapy. It has therefore been assumed ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0058-y
更新日期:2011-02-01 00:00:00
abstract::The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in p...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-014-0207-9
更新日期:2015-02-01 00:00:00
abstract::Small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) is a steroid receptor molecular co-chaperone that may substantially influence hormone action and, consequently, hormone-mediated carcinogenesis. To date, published studies describe SGTA as a protein that is potentially critical in a range of bio...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-013-0151-0
更新日期:2013-12-01 00:00:00
abstract::Residential characteristics in urban neighborhoods impact health and might be important factors contributing to health disparities, especially in the African American population. The purpose of this systematic review is to understand the relationship between urban neighborhood and residential factors and breast cancer...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0325-x
更新日期:2018-04-01 00:00:00
abstract::Castration-resistant prostate cancer (CRPC) is an androgen receptor (AR)-dependent disease expected to cause the death of more than 27,000 Americans in 2015. There are only a few available treatments for CRPC, making the discovery of new drugs an urgent need. We report that CUDC-101 (an inhibitor od HER2/NEU, EGFR and...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-016-0257-2
更新日期:2016-06-01 00:00:00
abstract::The authors conducted a cross-sectional study to investigate the associations of fat, fiber, and carbohydrate intake with endogenous estrogen, androgen, and insulin-like growth factor (IGF) levels among 595 premenopausal women. Overall, no significant associations were found between dietary intake of these macronutrie...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0050-6
更新日期:2010-10-01 00:00:00
abstract::Consumption of methylxanthine alkaloids appears to induce activities by antagonizing adenosine receptors, implicated in breast cancer behavior in vitro. Our goal was to evaluate expression of genes for methylxanthine receptors and metabolizing enzymes to assess risk of breast carcinoma recurrence. Clinical outcomes, e...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-017-0309-2
更新日期:2017-12-01 00:00:00
abstract::Ovarian cancer is the leading cause of death among gynecological malignancies. Chemotherapy alone is not sufficient to achieve long-term survival of the patient with advanced stage ovarian cancer. Although cancer immune therapy has long been expected as a new modality for ovarian cancer, very few trials have been clin...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-010-0046-2
更新日期:2010-12-01 00:00:00
abstract::In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and after PCa treatment ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0335-8
更新日期:2018-08-01 00:00:00
abstract::Oral contraceptive use is a well-established risk factor for breast cancer and is common among reproductive-aged women in the USA. Its relationship with less common, more aggressive, molecular subtypes is less clear. A population-based case-case analysis was conducted comparing three less common molecular subtypes to ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-019-00362-5
更新日期:2019-06-01 00:00:00
abstract::Oestrogen receptor alpha (ERα) is a ligand-dependent transcription factor that mediates oestrogen effects in hormone-responsive cells. Following oestrogenic activation, ERα directly regulates the transcription of target genes via DNA binding. MicroRNAs (miRNAs) represent a class of small noncoding RNAs that function a...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-012-0102-1
更新日期:2012-06-01 00:00:00
abstract::Lymphangioleiomyomatosis (LAM) is a female-predominant lung disease that can lead to respiratory failure. LAM cells typically have inactivating tuberous sclerosis 2 (TSC2) mutations, leading to mTORC1 hyperactivation. The gender specificity of LAM suggests that female hormones contribute to disease progression. Clinic...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-014-0192-z
更新日期:2014-10-01 00:00:00
abstract::We previously reported that an accelerated decline in circulating testosterone level is associated with a higher risk of prostate cancer (PCa). This study is to examine whether testosterone change rate is related to serum prostate-specific antigen (PSA) concentration among PCa-free men. Longitudinal data were derived ...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-019-00369-y
更新日期:2019-12-01 00:00:00
abstract::Thyroid hormone status has long been implicated in cancer development. Here we investigated the role of thyroxine (T4) in colorectal cancer cell lines HCT 116 (APC wild type) and HT-29 (APC mutant), as well as the primary cultures of cancer cells derived from patients. Cell proliferation was evaluated with standard as...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0324-y
更新日期:2018-06-01 00:00:00
abstract::The anti-diabetic drug metformin (1,1-dimethylbiguanide hydrochloride) reduces both the incidence and mortality of several types of cancer. Metformin has been shown to selectively kill cancer stem cells, and triple-negative breast cancer (TNBC) cell lines are more sensitive to the effects of metformin as compared to l...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-014-0188-8
更新日期:2014-12-01 00:00:00
abstract::Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen ...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-019-0358-9
更新日期:2019-06-01 00:00:00
abstract::Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a significant effort has been made to develop multinational, collaborative studies to better understand the pathogenes...
journal_title:Hormones & cancer
pub_type: 杂志文章,评审
doi:10.1007/s12672-015-0241-2
更新日期:2016-02-01 00:00:00
abstract::Breast cancer survivors are at an increased risk of second primary cancers, and the risk factors for the latter may have clinical significance. The aims of our study were to evaluate the incidences and risk factors of second primary female genital cancers (corpus uteri, cervix uteri plus ovary) in a large cohort of br...
journal_title:Hormones & cancer
pub_type: 杂志文章
doi:10.1007/s12672-018-0330-0
更新日期:2018-06-01 00:00:00